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because he’s 77 years old, would not 
be treated the way it’s treated in the 
United States. In other words, they say, 
well, he doesn’t have long to live, even 
if he’d live another four or five years. 
They’d say, well, we’ve got to spend the 
money on people that have more, can 
contribute more to the economy.”
That earned a rebuttal from Ara 
Darzi, Britain’s ambassador for health 
and life sciences. “Well, I’m sorry to 
say that’s the most ludicrous thing I’ve 
heard,” he told National Public Radio 
(where I work). He went on to say it’s 
not just false — “these are lies which 
have been used to set fear against 
reform.” He added that life expectancy 
in the UK is longer than it is in the US.
As the flap unfolded, the National 
Health Service found friends and 
supporters on both sides of the 
Atlantic.
“For the first couple of years I lived 
in Britain, I was an illegal immigrant 
from the United States, visaless with 
an expired passport and looking over 
my shoulder all the time,” wrote Clancy 
Sigal in the Los Angeles Times. “Even 
so, from the very first day I arrived at 
Victoria Station in London, suffering 
from bronchitis, I was accepted in the 
NHS — the national health scheme, 
we called it — no questions asked and 
no ID required.” For three decades, 
he used the free medical system, 
“and that single-payer, socialistic, 
government-run, bureaucratized, 
heavily used, nationalized health 
system served me — and 50 million 
others — very well.”
More visible – and vociferous — was 
the defence from the UK, from the 
likes of Prime Minister Gordon Brown 
and Conservative Party leader David 
Cameron. The latter sent out a widely 
quoted email proclaiming national 
pride in the NHS.
“One of the wonderful things about 
living in this country is that the moment 
you’re injured or fall ill — no matter 
who you are, where you are from, or 
how much money you’ve got — you 
know that the NHS will look after you.”
Of course, many misrepresentations 
are built on a grain of truth. And in 
this case, the truth is that health care 
is not a limitless resource — to make 
it affordable, the NHS does set limits 
about what it will cover. That doesn’t 
mean snuffing out the Ted Kennedys 
and Stephen Hawkings of the world, 
but it does mean reining in expenses.
So, when the British medical review 
institution — National Institute for 
Health and Clinical Excellence — 
concluded that controlled studies 
of cortisone for non-specific lower 
back pain showed that the shots 
don’t seem to work, it decided to 
recommend against them in that 
context. In the UK as well as the US, 
this was an outrage.
“Specialists fear tens of thousands 
of people, mainly the elderly and frail, 
will be left to suffer excruciating levels 
of pain or pay as much as £500 each 
for private treatment,” the Telegraph 
warned.
Sean Hannity on Fox News waved 
around that article as proof that 
America is heading toward a world 
of medical rationing and agony that 
would no doubt result from putting a 
price tag on human life and suffering.
The truth is, we already do, wrote 
Peter Singer in the New York Times 
magazine.
“Health care is a scarce resource, 
and all scarce resources are rationed 
in one way or another.” The real 
question — not currently up for 
debate — is whether to be honest and 
direct about what’s already happening.
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critics of potential health reforms, it 
underpins one of the largest projects 
hoping to exploit burgeoning genetic 
information.
The UK Biobank project aims to 
store biological samples from 500,000 
people aged between 40 and 69, 
along with other details of their health 
and lifestyle, to map any developing 
illnesses and their link with genes 
amongst the group.
The facility to store all these samples 
was opened this summer with 350,000 
people recruited and the target hoped 
to be reached next year. At the heart of 
the project is a hi-tech blood and urine 
store, the largest facility of its kind in 
the world which will keep 10 million 
samples at –80°C for the next 30 years 
or more. The project has incorporated 
specialist knowledge worldwide 
to ensure the samples are stored 
effectively for long periods.
“To talk about the sheer size detracts 
from the other, very real, achievements 
that have allowed us to develop a 
state-of-the-art facility that means we 
can store large quantities of blood and 
urine samples in the best conditions 
possible over decades, and retrieve 
them quickly and easily when the 
time comes,” says Tim Peakman, UK 
Biobank executive director.
Each sample of blood is stored in a 
number of aliquots and identified by a 
Britain’s health service may be under 
attack in the US but it is providing 
researchers with the base for a major 
health project. Nigel Williams reports.
Key data base unique bar code so that the individual donor remains anonymous. A frozen, 
frost-free storage environment is 
crucial if the bar codes are to be read 
and successfully retrieved in years to 
come.
“Frosting is one of our biggest 
concerns,” says Peakman. The solution 
is to ensure that the air circulating within 
the freezer is as dry as possible — as 
low as two parts per million of water 
vapour (compared with 10,000–12,000 
in the air on a relatively humid summer’s 
day) — so that frost cannot form and 
disable the robotics and make the bar 
codes on the tubes illegible. Water 
vapour is removed from compressed air 
dryers at the back of the store before 
feeding it into the system.
At the heart of the project 
is a hi-tech blood and urine 
store, the largest facility of 
its kind in the world which 
will keep 10 million samples 
at –80°C for the next  
30 years or more. 
The official opening of the facility 
was accompanied by an award of an 
additional £6 million by the Wellcome 
Trust, Medical Research Council 
and Department of Health to the £60 
million project, which is aimed to allow 
researchers to gather more information 
from participants including diet, fitness 
and physical activity levels. Biobank 
also plans to record information on 
participants’ eyes as eye health may 
be linked to many other disorders.
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research and development at the 
Department of Health said: “An 
important part of the Department 
of Health’s work is to stand behind 
research aimed at tackling health 
problems and improving NHS care. 
Because of its potential for future 
generations, the government is glad 
to join with the Wellcome Trust, the 
Medical Research Council and others 
in supporting UK Biobank. UK Biobank 
will help us understand how our 
children and our children’s children can 
live longer, healthier lives.”
UK Biobank writes to people to ask 
if they are willing to take part in the 
project. With their approval, it will track 
their health over the next 30 years but 
it is essentially an altruistic project.
The volunteers are invited to one 
of 20 local assessment centres, 
where they complete an automated 
questionnaire and are interviewed 
about lifestyle, medical history and 
nutritional habits. Basic variables such 
as weight, height, blood pressure, 
bone density, grip strength and lung 
function are measured and blood and 
urine samples are taken.
But there is not feedback to the 
volunteers. This is to ensure that 
participants are not compromised if 
they seek life assurance, says Biobank 
chief executive, Rory Collins.
Not surprisingly, some people are 
unhappy with the invitation that arrives 
in the mail. And some commentators 
worry that any access to the genetic 
data by the private sector might lead 
to profit being put before altruism. In 
July, the House of Lords science and 
technology committee issued a report 
calling for the NHS to do more to 
translate the advances in gene science 
into clinical practice but also for tighter 
regulation of “direct to consumer” 
genetic testing.
But the Department of Health, while 
acknowledging that harnessing genetic 
information offers great potential 
to develop new treatments, strict 
regulations are in place to ensure 
information is not used incorrectly. 
And other countries, also with 
access to patient data, have also 
been seeking to gather population-
based information. The Wellcome 
Trust announced new funding last 
month of £2.5 million for the Chinese 
Kadoorie Biobank Study, originally 
established in 2004 as a collaborative 
project between the University of 
Oxford’s clinical trial service unit, and On track: The UK Biobank stores millions of blood and urine samples from participants at a 
site near Manchester. (Photo: Wellcome Library, London.)the Chinese Centre for Disease Control 
and Prevention. The Kadoorie Biobank 
study has already recruited more than 
500,000 people aged between 35 and 
74 from both rural and urban areas 
throughout China.
Like the UK project, the aim is to 
study environmental and genetic 
factors involved in common conditions. 
The Biobank is integrated with China’s national systems of healthcare and 
disease surveillance. Zhengming Chen 
at the University of Oxford, who leads 
the UK arm of the project, said that 
China was uniquely placed for large-
scale medical research: “There is a 
great deal of unexplained variation in 
disease rate and risk exposure and 
a high incidence for many common 
conditions such as stroke.”
